Pomalidomide-PEG-Ph-NH2 is a derivative of Pomalidomide, a potent immunomodulatory drug, that has been conjugated with a PEG (polyethylene glycol) chain and a Ph-NH2 functional group.
PEGylation, the covalent attachment of PEG chains to therapeutic agents, has become a popular strategy for improving drug pharmacokinetics and pharmacodynamics. PEG chains can enhance the solubility, stability, and half-life of drugs, resulting in improved therapeutic efficacy and reduced toxicity. The Ph-NH2 functional group, on the other hand, provides an opportunity for targeted drug delivery and selective tumor accumulation.
Pomalidomide-PEG-Ph-NH2 has shown promising results in preclinical studies as a potential treatment for multiple myeloma and other hematological malignancies. The conjugate exhibits enhanced stability and improved pharmacokinetic properties compared to Pomalidomide alone, leading to increased antitumor activity and reduced side effects.
Pomalidomide-PEG-Ph-NH2
| Cat# | Name | Structure | Pricing |
|---|---|---|---|
| AP13280 | Pomalidomide-PEG4-Ph-NH2 | Pricing |
